Anti-Mouse CD154 – Biotin

Pricing & Details

Product No.C2349
Clone
MR1
Protein
CD154
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
CD40L, TRAP, T-BAM, CD40LG, HIGM1, IGM, IMD3, TNFSF5, gp39, hCD40L, CD40
Isotype
Armenian Hamster
IgG
Applications
FC
Prod No.
Size
Price
Avail.
Qty
Add to cart
C2349-50 µg
50 µg
$150.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Armenian Hamster
Immunogen
Activated mouse Th1 clone D1.6
Product Concentration
0.5 mg/ml
Formulation
This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this MR1 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone MR1 recognizes an epitope on mouse CD154.
Antigen Distribution
CD154 is expressed on activated CD4+ T cells.
Background
CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.

Antigen Details

Protein
Ligand/Receptor
CD40
PubMed
NCBI Gene Bank ID
Research Area
Costimulatory Molecules
.
Immunology
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.